Published in Drug Metab Dispos on June 13, 1981
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother (1998) 1.37
Influence of the unbound concentration of cefonicid on its renal elimination in isolated perfused rat kidneys. Antimicrob Agents Chemother (1991) 0.81
AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol (1998) 2.08
Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother (2001) 2.03
Radioimmunoassay for prednisolone. Steroids (1973) 1.81
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther (1997) 1.55
Surrogate biochemical markers: precise measurement for strategic drug and biologics development. J Clin Pharmacol (1995) 1.43
Biochemical site of regulation of bile acid biosynthesis in the rat. J Lipid Res (1970) 1.40
Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother (1998) 1.37
Estimating the accumulation of drugs. J Pharm Sci (1983) 1.37
Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother (2001) 1.34
Plasma protein binding of ceftriaxone. Xenobiotica (1987) 1.24
Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol (2000) 1.23
Feedback regulation of bile acid biosynthesis in the rat. J Lipid Res (1969) 1.22
Simultaneous pharmacokinetic and pharmacodynamic modeling. J Pharmacokinet Biopharm (1981) 1.13
Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther (1987) 1.13
A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther Drug Monit (1996) 1.12
Determination of 1,4-benzodiazepines and -diazepin-2-ones in blood by electron-capture gas-liquid chromatography. Anal Chem (1976) 1.12
Pharmacokinetics of diazepam following multiple-dose oral administration to healthy human subjects. J Pharmacokinet Biopharm (1977) 1.12
Plasma protein binding of diazepam after a single dose of sodium oleate. J Pharm Sci (1978) 1.10
Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats. Antimicrob Agents Chemother (1998) 1.09
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther (2001) 1.09
Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol (2000) 1.04
Pharmacokinetics of erythromycin on repetitive dosing. J Clin Pharmacol (1977) 1.04
Improved synthesis of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). J Lipid Res (1969) 1.01
Interaction of chloramphenicol with phenytoin and phenobarbital. Case report. Clin Pharmacol Ther (1978) 0.98
Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol (1985) 0.97
Food increases the bioavailability of isotretinoin. J Clin Pharmacol (1984) 0.96
Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain. Clin Pharmacol Ther (1990) 0.96
Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol (1999) 0.96
Determination of clonazepam and flunitrazepam in blood by electron-capture gas-liquid chromatography. J Chromatogr (1974) 0.94
Quantitation of free and total amphotericin B in human biologic matrices by a liquid chromatography tandem mass spectrometric method. Ther Drug Monit (2001) 0.89
Use of the isolated perfused kidney as a tool in drug disposition studies. Drug Metab Rev (1983) 0.88
Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection. J Chromatogr (1987) 0.88
Pharmacokinetic model for diazepam and its major metabolite desmethyldiazepam following diazepam administration. J Pharm Sci (1983) 0.88
Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc (1998) 0.87
Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther (1982) 0.87
An evolution of drug development and clinical pharmacology during the 20th century. J Clin Pharmacol (2000) 0.87
Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J Clin Pharmacol (1988) 0.86
Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant (1998) 0.86
The clinical pharmacokinetics of quinapril. Angiology (1989) 0.86
The determination of 7-chloro-1,3-dihydro-5-(2',chlorophenyl)-2H-1,4-benzodiazepin-2-one (Ro 5-3027) and its metabolite (lorazepam) in blood and urine by electron-capture gas liquid chromatography. J Chromatogr Sci (1973) 0.85
A new radioimmunoassay for haloperidol: direct measurement of serum and striatal concentrations. J Pharmacol Exp Ther (1981) 0.85
Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution. Crit Care Med (1996) 0.84
Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos (2001) 0.84
Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1988) 0.83
Recipient preconditioning and donor-specific bone marrow infusion in a pig model of total bowel transplantation. Transplantation (1997) 0.83
Thalidomide dose proportionality assessment following single doses to healthy subjects. J Clin Pharmacol (2001) 0.83
Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet (1985) 0.83
Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation (2000) 0.82
Controversy. IV: Population pharmacokinetics, NONMEM and the pharmacokinetic screen; academic, industrial and regulatory perspectives. J Clin Pharmacol (1989) 0.82
A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. Transplantation (1995) 0.82
Pharmacokinetics of isotretinoin following a single oral dose. J Clin Pharmacol (1982) 0.81
Differences in oral verapamil absorption as a function of time of day. J Clin Pharmacol (1989) 0.81
Pharmacokinetic analysis of concentration-time data obtained following administration of drugs that are recycled in the bile. J Pharm Sci (1984) 0.81
Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol (1998) 0.81
In utero-exposure to saccharin: a threat? Cancer Lett (1986) 0.80
Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation (2000) 0.80
Pharmacokinetic interpretation of plasma cortisol and cortisone concentrations following a signle oral administration of cortisone acetate to human subjects. J Clin Pharmacol (1980) 0.80
Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J Interferon Res (1985) 0.80
Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol (1983) 0.80
Metabolism of salicylic acid in the isolated perfused rat kidney. Interconversion of salicyluric and salicyclic acids. Drug Metab Dispos (1981) 0.80
Pharmacokinetics of drugs during various detoxification procedures for overdose and environmental exposure. Drug Metab Rev (1982) 0.80
Acetylation of sulfisoxazole by isolated perfused rat kidney. J Pharm Sci (1980) 0.80
Radioimmunoassay for prednisone. Steroids (1974) 0.80
Pharmacokinetics of multiple oral doses of selected polychlorinated biphenyls in mice. Toxicol Appl Pharmacol (1979) 0.80
Theophylline dosage adjustment during enoxacin coadministration. Antimicrob Agents Chemother (1990) 0.80
Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol (1999) 0.79
Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin. Anesth Analg (2001) 0.79
A time-dependent volume of distribution term used to describe linear concentration-time profiles. J Pharmacokinet Biopharm (1983) 0.79
Pharmacokinetics of a single intramuscular injection of vitamin E to premature neonates. Pediatr Pharmacol (New York) (1983) 0.79
Verapamil pharmacodynamics after intravenous and oral dosing: theoretic consideration. J Clin Pharmacol (1986) 0.79
Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologic/toxicologic effects of drugs. Drug Metab Rev (1980) 0.78
A pharmacokinetic model for enterohepatic recirculation in the rat: phenolphthalein, a model drug. Drug Metab Dispos (1979) 0.78
Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharm Drug Dispos (2000) 0.78
Absorption of saccharin from rat urinary bladder. J Pharm Sci (1978) 0.78
Role of gut contents, intestinal wall, and liver on the first pass metabolism and absolute bioavailability of isotretinoin in the dog. Drug Metab Dispos (1983) 0.77
Pharmacokinetics of the retinoids isotretinoin and etretinate. A comparative review. J Am Acad Dermatol (1982) 0.77
Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses. Biopharm Drug Dispos (1992) 0.77
Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. Ther Drug Monit (1997) 0.77
A preliminary report on the pharmacokinetics of saccharin in man: single oral dose administration. J Clin Pharmacol (1981) 0.77
Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs. J Pharm Sci (1982) 0.77
Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon. Eur J Clin Pharmacol (1985) 0.77
Effects of polyaspartic acid on pharmacokinetics of tobramycin in two strains of rat. Antimicrob Agents Chemother (1994) 0.77
A pharmacokinetic model to differentiate preabsorptive, gut epithelial, and hepatic first-pass metabolism. J Pharmacokinet Biopharm (1979) 0.77
Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol (2000) 0.77
A nonradioactive iothalamate method for measuring glomerular filtration rate and its use to study the renal handling of cibenzoline. Ther Drug Monit (1988) 0.76
Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther (1980) 0.76
FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc (1998) 0.76
Dietary saccharin kinetics. Clin Pharmacol Ther (1981) 0.76
Bile acid synthesis in the isolated, perfused rabbit liver. J Clin Invest (1971) 0.76
Pharmacokinetics of isotretinoin and its major blood metabolite following a single oral dose to man. Eur J Clin Pharmacol (1983) 0.76
Influence of gut microflora on bioavailability. Drug Metab Rev (1979) 0.76
Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. Transplant Proc (1998) 0.76
Pharmacokinetics of saccharin in the rat. Renal clearance in vivo and in the isolated perfused kidney. Drug Metab Dispos (1980) 0.76
Time course of carbamazepine self-induction. J Pharmacokinet Biopharm (1979) 0.76